Terms: = Sarcomas AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Prognosis
46 results:
1. Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
Bremmer F; Pongratanakul P; Skowron M; Che Y; Richter A; Küffer S; Reuter-Jessen K; Bohnenberger H; Pauls S; Kresbach C; Schüller U; Stühler K; Ströbel P; Albers P; Nettersheim D
Br J Cancer; 2023 Nov; 129(10):1580-1589. PubMed ID: 37726478
[TBL] [Abstract] [Full Text] [Related]
2. The usefulness of immunohistochemistry for phosphohistone H3 as a prognostic factor in myxoid liposarcoma.
Takazawa A; Yoshimura Y; Okamoto M; Tanaka A; Kito M; Aoki K; Uehara T; Takahashi J; Kato H; Nakayama J
Sci Rep; 2023 Mar; 13(1):4733. PubMed ID: 36959285
[TBL] [Abstract] [Full Text] [Related]
3. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract] [Full Text] [Related]
4. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
Xie L; Chen C; Liang X; Xu J; Sun X; Sun K; Yang R; Tang X; Guo W
Orthop Surg; 2023 Mar; 15(3):829-838. PubMed ID: 36519392
[TBL] [Abstract] [Full Text] [Related]
5. Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis.
Pala L; Bagnardi V; Tettamanzi F; Barberis M; Mazzarol G; Casali C; De Pas T; Pennacchioli E; Coppola S; Baldini F; Cocorocchio E; Ferrucci P; Patane' D; Saponara M; Queirolo P; Conforti F
Mol Diagn Ther; 2023 Jan; 27(1):5-13. PubMed ID: 36401787
[TBL] [Abstract] [Full Text] [Related]
6. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Gan M; Zhang C; Qiu L; Wang Y; Bao H; Yu R; Liu R; Wu X; Shao Y; Hou P; Fei Z
Cancer Med; 2022 Nov; 11(21):4070-4078. PubMed ID: 35586877
[TBL] [Abstract] [Full Text] [Related]
7. GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi's Sarcoma-Associated Herpesvirus-Induced Cellular Transformation.
Wei S; Lu S; Liang L; Wang X; Li W; Li T; Chen L; Ju E; Zhang X; Lai Z; Huang Y; Lu X; Gao SJ
mBio; 2021 Dec; 12(6):e0343121. PubMed ID: 34933446
[TBL] [Abstract] [Full Text] [Related]
8. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
[TBL] [Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract] [Full Text] [Related]
10. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.
Whittle SB; Offer K; Roberts RD; LeBlanc A; London C; Majzner RG; Huang AY; Houghton P; Alejandro Sweet Cordero E; Grohar PJ; Isakoff M; Bishop MW; Stewart E; Slotkin EK; Greengard E; Borinstein SC; Navid F; Gorlick R; Janeway KA; Reed DR; Hingorani P
Pediatr Blood Cancer; 2021 Sep; 68(9):e29188. PubMed ID: 34137164
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
Luo C; Xin H; Yin D; Zhao T; Hu Z; Zhou Z; Sun R; Yao N; Sun Q; Fan J; Huang X; Zhou J; Zhou S
Aging (Albany NY); 2021 Jun; 13(11):15126-15138. PubMed ID: 34081621
[TBL] [Abstract] [Full Text] [Related]
12. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings.
Khanna L; Prasad SR; Yedururi S; Parameswaran AM; Marcal LP; Sandrasegaran K; Tirumani SH; Menias CO; Katabathina VS
Radiographics; 2021; 41(3):876-894. PubMed ID: 33891523
[TBL] [Abstract] [Full Text] [Related]
13. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience.
Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
[TBL] [Abstract] [Full Text] [Related]
14. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of a first-in-class EZH2 selective degrader.
Ma A; Stratikopoulos E; Park KS; Wei J; Martin TC; Yang X; Schwarz M; Leshchenko V; Rialdi A; Dale B; Lagana A; Guccione E; Parekh S; Parsons R; Jin J
Nat Chem Biol; 2020 Feb; 16(2):214-222. PubMed ID: 31819273
[TBL] [Abstract] [Full Text] [Related]
17. [SMARCA4-deficient primary thoracic sarcoma:a clinicopathological analysis of five cases].
Zheng MJ; Zheng Q; Wang Y; Shen L; Zhu XZ; Li Y
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):537-542. PubMed ID: 31288309
[No Abstract] [Full Text] [Related]
18. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-fgfr1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract] [Full Text] [Related]
19. B7-H3 and its role in bone cancers.
He L; Li Z
Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
[TBL] [Abstract] [Full Text] [Related]
20. Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.
Zhang J; Liu M; Liu W; Wang W
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1207-1215. PubMed ID: 30942624
[TBL] [Abstract] [Full Text] [Related]
[Next]
